Autologous haematopoietic stem cell transplantation in lymphomas: clinical outcomes

Autologous hematopoietic stem cell transplantation (HSCT) is widely used in treatment of Hodgkin and non-Hodgkin lymphomas. The article represents the results of HSCT among 124 patients with Hodgkin and non-Hodgkin lymphomas, treated from 2005 to 2012 in Pirogov’s center hematology department. According to the study, the estimated 5-year progression-free survival (PFS) was 64% and 5-year overall survival (OS) was 72%. The estimated 2-year overall survival in patients with chemosensitive relapse (complete or partial response) was 91,4%, whereas in group with resistant disease was 35,7%. The results of our study confirmed international data of effectiveness HSCT in lymphoma patients.